The history of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated substantial returns, the expiration of its patent opened the door to cheaper competitors, dramatically eroding revenue. This presents a unique risk for firms banking on related blockbuster offerings, suggesting that a care

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. Originally a blockbuster drug, generating billions in sales , its patent expiration created a deluge of lower-priced alternatives , significantly impacting its position . While some businesses may seek to capitalize on similar conditions , the pre